Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metasta
(8-January-2018)
Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metastatic breast cancer.